KDR and neoplasm: Numerous preclinical studies in melanoma models have explored CAR T cell approaches targeting various tumor antigens including CD16 [44], HER2 [45], GP100-HLA-A2 complex [46], CD126 [47], VEGFR-2 [48], CD20 & MCSP [49], MCSP [50], gp100 and MCSP [51], GD2 [52], GD3 [53], B7-H3 [54], and CD70 [55].